cladribine
Selected indexed studies
- Cladribine (Mavenclad) for multiple sclerosis. (Med Lett Drugs Ther, 2019) [PMID:31381552]
- [Cladribine]. (Gan To Kagaku Ryoho, 2003) [PMID:12610885]
- Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions. (Clin Pharmacokinet, 2022) [PMID:34894346]
_Worker-drafted node — pending editorial review._
Connections
cladribine is a side effect of
Sources
- Cladribine (Mavenclad) for multiple sclerosis. (2019) pubmed
- [Cladribine]. (2003) pubmed
- Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions. (2022) pubmed
- Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. (2020) pubmed
- Cladribine (2-chlorodeoxyadenosine). (1992) pubmed
- Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. (2018) pubmed
- Cladribine: mechanisms and mysteries in multiple sclerosis. (2018) pubmed
- Cladribine Tablets: A Review in Relapsing MS. (2018) pubmed
- Cladribine for people with multiple sclerosis. (2026) pubmed
- Cladribine to Treat Relapsing Forms of Multiple Sclerosis. (2017) pubmed